Stock Analiz

Volitionrx Ltd. VNRX

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2015 · data as of November 13, 2026

$0.23Market cap $8M
Open the interactive analysis →

Volitionrx Ltd. (VNRX) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$24M, a net margin of -698.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 164% a year, a 5-year average ROIC of -708%.

About Volitionrx

Volitionrx is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2015. Revenue went from $14785 in 2014 to $2M in 2025, growth of about 54.2% a year. It was profitable in 0 of the last 10 years in our data. It spends 584% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.4
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-248.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)40.0%
Revenue growth (5 yrs, per year)164.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-9620.8%
ROIC (5-yr avg.)-707.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3M$2M$1M$775302$306392$90035$13433$17096———
Net income-$24M-$23M-$27M-$36M-$31M-$27M-$20M-$16M-$18M-$15M-$12M
Free cash flow-$21M-$20M-$26M-$19M-$17M-$22M-$18M-$13M-$15M-$14M-$9M
EPS (diluted)$-0.68$-0.66$-0.93$-1.50—$-1.53$-1.35$-1.23$-1.71$-1.68$-1.56
Net margin-698.5%-1352.2%-2186.3%-4601.7%-9986.7%-29977.0%-151900.0%-94168.6%———
ROIC————-1310.2%-105.7%-84.0%-72.7%-97.2%-99.1%-45.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $13.62, 5823% above the current price; targets range from $2.00 to $24.00; the consensus rating is “none”; expected EPS is $-2.00 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Volitionrx pay a dividend?

Not currently.

Is Volitionrx a good stock to buy?

We do not give buy or sell advice. Volitionrx scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.